Craig Gracey, serving as the Chief Accounting Officer for Omada Health, Inc. (NASDAQ:OMDA), has finalized a sequence of stock transactions resulting in proceeds of $85,423. The filings, lodged as an amended Form 4/A with the Securities and Exchange Commission on July 8, 2026, disclose both the sales of common stock and the concurrent acquisition of shares through option exercises. The amendment served to correct an initial report filed on June 30, 2026, which had inadvertently omitted the acquisition details, thereby understating the total securities beneficially owned by Gracey following the sales.
The liquidation activities were carried out in two distinct phases during late June. On June 26, 2026, Gracey sold 2,084 shares of Omada Health common stock at a price point of $20.00 per share. Three days later, on June 29, 2026, an additional 2,083 shares were sold at $21.00 per share. These dispositions were executed pursuant to a 10b5-1 trading plan adopted on March 13, 2026. Such plans permit corporate insiders to establish predetermined schedules for buying or selling company stock, insulating the transactions from allegations of trading on material non-public information.
Simultaneously with these sales, Gracey acquired shares of common stock through the exercise of stock options. On June 26, he acquired 2,084 shares at an exercise price of $6.57 per share. On June 29, he acquired an additional 2,083 shares at the identical price of $6.57. The total value of shares acquired through these specific option exercises amounted to $27,377. The options exercised are derived from a grant structured to vest over a four-year period, with 25% of the grant vesting on the first anniversary of September 9, 2024, and the remaining balance vesting on a monthly basis thereafter.
Following the completion of these reported transactions, Gracey's direct holdings in Omada Health stand at 15,441 shares of common stock. In addition to his direct equity position, he retains 35,417 stock options. The executive's activity unfolds against a backdrop of significant stock price movement for Omada Health. The company's shares have posted strong returns, climbing 49% over the past six months. At the time of reporting, the stock was trading at $22.98, a level near its 52-week high of $26.91. Market data indicates the stock closed at $22.98, with after-hours trading reflecting a slight decline to $22.85.
Financial context surrounding the company includes reports of profitability approaching for Omada Health, which has remained unprofitable over the last twelve months. Analysts predict the company will achieve profitability this year, with an earnings per share (EPS) forecast of $0.34. However, conflicting views exist regarding valuation. InvestingPro analysis suggests the stock may be overvalued at current levels, placing it among companies on the Most Overvalued list. This contrasts with recent fundamental performance, as Omada Health reported financial results for the first quarter of 2026 that showcased a positive earnings surprise. The company achieved an EPS of -$0.05, exceeding the anticipated loss of -$0.08. Additionally, Omada Health reported revenue of $78 million, representing a 42% increase compared to the previous year.
Market sentiment has also been influenced by analyst actions. Citizens has raised its price target for Omada Health to $21 from $18, maintaining a Market Outperform rating. The firm cited the company's growth outlook as a primary driver for the upgrade. Citizens analyst Constantine Davides highlighted that Omada Health has been trading between 1.3 and 6.6 times its forward revenue since its June 2025 IPO. This valuation multiple provides context for the current price levels and the executive's decision to liquidate shares.
Corporate governance developments also marked the period. Omada Health held its 2026 Annual Meeting of Stockholders, where significant leadership changes were ratified. Sean Duffy and Trevor Fetter were elected as Class I Directors. Duffy received 18,540,089 votes in favor, while Fetter garnered 18,538,042 votes. Both directors are set to serve until the 2029 annual meeting. These developments reflect ongoing investor interest and strategic decisions influencing Omada Health's trajectory. The combination of executive trading activity, shifting analyst ratings, and corporate governance updates provides a multifaceted view of the company's current standing in the market.